Safety & Regulations
Your health and safety come first. Review these guidelines, understand the current regulatory landscape, and always work with qualified professionals.
Medical Disclaimer
The information on this website is for educational and research purposes only. It is not medical advice and should not be used as a substitute for professional medical consultation. Peptides are powerful bioactive compounds — improper use can cause harm. Always consult a qualified healthcare provider before starting any peptide protocol.
Always Consult a Physician
Before starting any peptide protocol, consult with a qualified healthcare provider experienced in peptide therapy. This is not optional — it is essential for your safety. A knowledgeable physician can order baseline bloodwork, monitor your response, adjust dosing, and identify contraindications specific to your health profile.
Source Quality Matters
The quality of peptides varies enormously between suppliers. Only use peptides from reputable, third-party tested sources that provide Certificates of Analysis (COA). Contaminated or degraded peptides can cause adverse reactions. Look for HPLC purity testing (should be >98%), endotoxin testing, and proper lyophilization. Never use peptides from unverified sources.
Monitor Your Health
Regular bloodwork is critical. At minimum, check: complete blood count, comprehensive metabolic panel, IGF-1 levels (if using GH peptides), fasting insulin and glucose, liver and kidney function, and hormone panels relevant to your protocol. Get baseline labs before starting and recheck every 4–8 weeks during a cycle.
Dosing Principles
Always start with the lowest recommended dose and titrate upward slowly. More is not better with peptides — many have a therapeutic window where higher doses increase side effects without additional benefit. Follow established research protocols and never exceed recommended dosages. If you experience adverse effects, reduce the dose or discontinue.
Cycling is Essential
Most peptides require cycling (periods on and off) to prevent receptor desensitization. Continuous use often leads to diminishing returns and may increase risk of side effects. Follow recommended cycle lengths: typically 4–12 weeks on, with 2–8 weeks off. Some FDA-approved peptides are designed for continuous use — follow your physician's guidance.
Safe Administration
For injectable peptides: use sterile technique, bacteriostatic water for reconstitution, insulin syringes, and alcohol swabs. Rotate injection sites. Store reconstituted peptides refrigerated (2–8°C) and use within the recommended timeframe (typically 4–6 weeks). Never share needles or vials. Dispose of sharps properly.
2026 Regulatory Updates
Category 2 Reclassification Review
Several popular peptides including BPC-157, TB-500, and others are under review for potential reclassification to Category 1, which would increase restrictions on availability.
FDA-Approved Peptides
Semaglutide (Ozempic/Wegovy), Tirzepatide (Mounjaro/Zepbound), PT-141 (Vyleesi), and Tesamorelin remain FDA-approved for specific indications through standard medical channels.
Compounding Regulations
FDA continues to update guidance on compounding pharmacies and their ability to produce peptide preparations. Changes may affect availability of certain compounds.
Research Use Classification
Several peptides including IGF-1 LR3, Follistatin-344, and Dihexa are classified as research-use only and are not approved for human therapeutic use.